CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCC
CheckMate 214 trial update
RCC Panel Reacts to Long-Term Follow-Up From CheckMate 214
ASCO GU24 special: Prof. Nizar Tannir shares CheckMate 214 results
Phase 3 CheckMate - 214
CheckMate 214: 4-Year Follow-up and Subgroup Analysis of Patients Without Nephrectomy
Key RCC data: JAVELIN Renal 101 & CheckMate 214
Renal cell carcinoma: the Emulsion and CheckMate 214 trials
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
CheckMate 214, KEYNOTE-564, and Updates in Treatment Approaches to nccRCC
CheckMate 214: Risk-Group Considerations and Combination Preferences
CheckMate 214 trial in RCC updates
Dr. Hammers on the CheckMate-214 Study for RCC
mRCC: Impact of CABOSUN and CheckMate-214
The relationship between health-related QoL and clinical outcomes in aRCC patients in CheckMate 214
First-line therapy options for RCC: lessons from CheckMate 214 and KEYNOTE-427
CheckMate-214: Nivolumab/Ipilimumab for mRCC?
Bradley McGregor, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in RCC patients
CheckMate 214: nivolumab + ipilimumab or sunitinib in patients with advanced renal cell carcinoma
Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC
